Literature DB >> 22118225

Intestinal colonization by enteroaggregative Escherichia coli supports long-term bacteriophage replication in mice.

Damien Maura1, Eric Morello, Laurence du Merle, Perrine Bomme, Chantal Le Bouguénec, Laurent Debarbieux.   

Abstract

Bacteriophages have been known to be present in the gut for many years, but studies of relationships between these viruses and their hosts in the intestine are still in their infancy. We isolated three bacteriophages specific for an enteroaggregative O104:H4 Escherichia coli (EAEC) strain responsible for diarrhoeal diseases in humans. We studied the replication of these bacteriophages in vitro and in vivo in a mouse model of gut colonization. Each bacteriophage was able to replicate in vitro in both aerobic and anaerobic conditions. Each bacteriophage individually reduced biofilms formed on plastic pegs and a cocktail of the three bacteriophages was found to be more efficient. The cocktail was also able to infect bacterial aggregates formed on the surface of epithelial cells. In the mouse intestine, bacteriophages replicated for at least 3 weeks, provided the host was present, with no change in host levels in the faeces. This model of stable and continuous viral replication provides opportunities for studying the long-term coevolution of virulent bacteriophages with their hosts within a mammalian polymicrobial ecosystem.
© 2011 Society for Applied Microbiology and Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 22118225     DOI: 10.1111/j.1462-2920.2011.02644.x

Source DB:  PubMed          Journal:  Environ Microbiol        ISSN: 1462-2912            Impact factor:   5.491


  43 in total

1.  Subdiffusive motion of bacteriophage in mucosal surfaces increases the frequency of bacterial encounters.

Authors:  Jeremy J Barr; Rita Auro; Nicholas Sam-Soon; Sam Kassegne; Gregory Peters; Natasha Bonilla; Mark Hatay; Sarah Mourtada; Barbara Bailey; Merry Youle; Ben Felts; Arlette Baljon; Jim Nulton; Peter Salamon; Forest Rohwer
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-19       Impact factor: 11.205

2.  Virulence of the Shiga toxin type 2-expressing Escherichia coli O104:H4 German outbreak isolate in two animal models.

Authors:  Tonia Zangari; Angela R Melton-Celsa; Aruna Panda; Nadia Boisen; Mark A Smith; Ivan Tatarov; Louis J De Tolla; James P Nataro; Alison D O'Brien
Journal:  Infect Immun       Date:  2013-02-25       Impact factor: 3.441

3.  Safety of using Escherichia coli bacteriophages as a sanitizing agent based on inflammatory responses in rats.

Authors:  Ji-Yeon Hwang; Jung-Eun Kim; Yoon-Jae Song; Jong-Hyun Park
Journal:  Food Sci Biotechnol       Date:  2016-02-29       Impact factor: 2.391

Review 4.  Microbiome therapeutics - Advances and challenges.

Authors:  Mark Mimee; Robert J Citorik; Timothy K Lu
Journal:  Adv Drug Deliv Rev       Date:  2016-05-05       Impact factor: 15.470

Review 5.  Engineering microbes for targeted strikes against human pathogens.

Authors:  In Young Hwang; Hui Ling Lee; James Guoxian Huang; Yvonne Yijuan Lim; Wen Shan Yew; Yung Seng Lee; Matthew Wook Chang
Journal:  Cell Mol Life Sci       Date:  2018-05-07       Impact factor: 9.261

6.  Bacteriophage Therapy Testing Against Shigella flexneri in a Novel Human Intestinal Organoid-Derived Infection Model.

Authors:  Alejandro Llanos-Chea; Robert J Citorik; Kourtney P Nickerson; Laura Ingano; Gloria Serena; Stefania Senger; Timothy K Lu; Alessio Fasano; Christina S Faherty
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-04       Impact factor: 2.839

Review 7.  Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies.

Authors:  Krystyna Dąbrowska; Stephen T Abedon
Journal:  Microbiol Mol Biol Rev       Date:  2019-10-30       Impact factor: 11.056

8.  Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections.

Authors:  Marine Henry; Rob Lavigne; Laurent Debarbieux
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

9.  Virulent bacteriophages can target O104:H4 enteroaggregative Escherichia coli in the mouse intestine.

Authors:  Damien Maura; Matthieu Galtier; Chantal Le Bouguénec; Laurent Debarbieux
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

Review 10.  Steering Phages to Combat Bacterial Pathogens.

Authors:  James Gurney; Sam P Brown; Oliver Kaltz; Michael E Hochberg
Journal:  Trends Microbiol       Date:  2019-11-16       Impact factor: 17.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.